0001415889-24-015151.txt : 20240603 0001415889-24-015151.hdr.sgml : 20240603 20240603161510 ACCESSION NUMBER: 0001415889-24-015151 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240530 FILED AS OF DATE: 20240603 DATE AS OF CHANGE: 20240603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GORDON CARL L CENTRAL INDEX KEY: 0001282930 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 241013770 MAIL ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811173868 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-314-6297 MAIL ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 form4-06032024_040605.xml X0508 4 2024-05-30 0001664710 Keros Therapeutics, Inc. KROS 0001282930 GORDON CARL L C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 true false false false 0 Stock Option (right to buy) 46.31 2024-05-30 4 A 0 10000 0 A 2034-05-29 Common Stock 10000 10000 D The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP. /s/ Keith Regnante, Attorney-in-Fact 2024-06-03